Success Story: EB-1A Approved After RFE! Our Firm Assisted an Egyptian Expert in Securing Success under Premium Processing
Client’s Testimonial:
"CASE APPROVED YAAAAAAAAAAAAAAAKSS. THANK YOU VERY MUCH."
On April 13th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for an Expert in the Field of Clinical Medicine (Approval Notice).
General Field: Clinical Medicine
Country of Origin: Egypt
State of Residence at the Time of Filing: New York
Approval Notice Date: April 13th, 2026
Processing Time: 2 months and 8 days (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (NAILG) is pleased to share the successful approval for an expert in clinical medicine in just over 2 months under premium processing, despite the issuance of a Request for Evidence (RFE) along the way. Holding an MBBCh degree, this professional approached NAILG seeking support in securing permanent residency through the EB-1A (Alien of Extraordinary Ability) category.
After a thorough review of the achievements and their impact on the field, we prepared a compelling petition that led to approval of the I-140 EB-1A filing. Although an RFE was issued, our team promptly prepared a comprehensive response that highlighted not only the objective metrics of academic success but also the work's real-world impact. This approval underscores extraordinary influence in cardiology and cardiovascular medicine.
Accomplishments and Expertise
Establishing a strong reputation as a leading researcher in clinical medicine, this professional has developed particular expertise in cardiology and cardiovascular medicine. Much of the work focuses on synthesizing high-quality clinical evidence to inform treatment guidelines and improve patient outcomes across a range of cardiovascular and medical conditions. These contributions have been especially influential in shaping international clinical practice guidelines and advancing innovative screening technologies to improve the early detection and management of cardiac conditions in diverse patient populations.
In support of the EB-1A petition, we highlighted several objective achievements, including:
- 46 peer-reviewed journal articles (with 15 first-authored), 1 forthcoming article (first-authored), 35 abstracts (including 12 first-authored), and 1 preprint
- 67 completed peer reviews for top-ranked journals
- Hundreds of citations + 15 Guidelines Citations from researchers across 45 countries.
Letters of Recommendation
To further support the petition, we obtained two expert letters of recommendation. One expert remarked:
"[Client] is a distinguished member of the clinical medicine field who has and continues to contribute valuable research for advancing evidence-based cardiovascular and cardiac surgical care. Through rigorous systematic reviews, meta-analyses of randomized clinical trials, and clinically focused outcomes research, [Client] has helped resolve longstanding uncertainties in perioperative management and informed safer, more effective treatment strategies adopted by the medical community."
EB-1A Approval and Outlook
NAILG is honored to have represented this extraordinary researcher in a successful EB-1A petition and looks forward to seeing the continued contributions that will be made to advancing cardiovascular medicine and improving patient care in the United States.